AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 37972659
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of FGFRi and MEK inhibition in an in vivo animal model
Trial: 37972895
Drug: Whole-food omnivorous
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-food omnivorous meal (MEAT) containing 100 g lean ground beef, 0.45 g protein/kg body mass
Trial: 37972929
Drug: Ankle block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ankle block (30 ml of ropivacaine 0.5%)
Trial: 37972929
Drug: Sciatic nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sciatic nerve block at the popliteal crease (30 ml of ropivacaine 0.5% + saphenous nerve block)
Trial: 37973472
Drug: Electroacupuncture (EA1)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroacupuncture (EA1) - Local EA with two abdominal acupoints, administered daily for 4 days.
Trial: 37973472
Drug: Electroacupuncture (EA2)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroacupuncture (EA2) - Local plus distal EA with twelve peripheral acupoints, administered daily for 4 days.
Trial: 37973472
Drug: Control -
RxNorm normalized name: HISTAMINE 6 mg in 1 mL PERCUTANEOUS INJECTION [Positive Skin Test Control - Histamine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control - Conventional standard-of-care therapy for AP, no EA treatment.
Trial: 37973545
Drug: Peanut, sesame
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peanut, sesame and tree nut allergy assessment through skin testing, specific IgE measurements and oral food challenges.
Trial: 37973713
Drug: Presence of
RxNorm normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Presence of drug resistance mutations
Trial: 37973784
Drug: Monoclonal antibodies
RxNorm normalized name: Monoclonal antibodies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monoclonal antibodies (mAbs) or antiviral drugs for COVID-19
Trial: 37973784
Drug: Other drug
RxNorm normalized name: Other drugs for bile therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other drug treatment strategies (control group)
Trial: 37973795
Drug: Carborie (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carborie (400 ml)
Trial: 37973795
Drug: Plain water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plain water (400 ml)
Trial: 37973856
Drug: Intracoronary glycoprotein
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary glycoprotein IIb/IIIa inhibitors
Trial: 37974056
Drug: Limosilactobacillus reuteri
RxNorm normalized name: Limosilactobacillus reuteri
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Limosilactobacillus reuteri ATCC PTA 4659 at high dose (1 × 10^11 CFU/day)
Trial: 37974056
Drug: Limosilactobacillus reuteri
RxNorm normalized name: Limosilactobacillus reuteri
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Limosilactobacillus reuteri ATCC PTA 4659 at low dose (1 × 10^9 CFU/day)
Trial: 37974084
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of norepinephrine
Trial: 37974160
Drug: Ketamine infusions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine infusions (up to eight infusions, twice-weekly over four weeks)
Trial: 37974160
Drug: Midazolam (active
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (active comparator, twice-weekly over four weeks)
Trial: 37974184
Drug: Intravenous idursulfase
RxNorm normalized name: Idursulfase
DrugBank: Idursulfase (DB01271)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous idursulfase
Trial: 37974280
Drug: Cerebral oximetry
RxNorm normalized name: Sus scrofa cerebral cortex preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cerebral oximetry monitoring plus treatment guideline
Trial: 37975059
Drug: Intravenous branched
RxNorm normalized name: Machilus thunbergii branch extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous branched chain amino acids (IV-BCAA) - 500 mL/day for 3 days + Lactulose; n = 39
Trial: 37975371
Drug: Adjuvant Tislelizumab
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant Tislelizumab plus chemotherapy (XELOX regimen: Xeloda plus Oxaliplatin)
Trial: 37975371
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy alone (XELOX regimen)
Trial: 37975501
Drug: Intercostal nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intercostal nerve block with patient-controlled intravenous analgesia (ICNB-PCIA)
Trial: 37976067
Drug: DAPT (Aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DAPT (Aspirin 100 mg/d + Clopidogrel 75 mg/d)
Trial: 37976073
Drug: 2 h-double
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 h-double dose of TDF/FTC (two pills)
Trial: 37976073
Drug: 7 days-single
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 7 days-single dose of TDF/FTC (daily pill)
Trial: 37976073
Drug: Comparison between
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison between 2 h-double dose and 7 days-single dose
Trial: 37976073
Drug: 2 h-double
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 h-double dose of TDF/FTC
Trial: 37976072
Drug: Fluvoxamine 100
RxNorm normalized name: fluvoxamine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvoxamine 100 mg twice daily (50 mg twice daily on day 1 followed by 100 mg twice daily for 12 additional days)
Trial: 37976257
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of MBSR and CCT
Trial: 37976391
Drug: Terlipressin (median
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terlipressin (median daily dose 4.3 mg/day, mean duration 6.4 days)
Trial: 37976391
Drug: Pretreatment biomarkers
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pretreatment biomarkers (CysC > 2.2 mg/l)
Trial: 37976391
Drug: Pretreatment biomarkers
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pretreatment biomarkers (N-terminal proBNP > 350 pg/mL)
Trial: 37976444
Drug: Tiragolumab 600
RxNorm normalized name: Tiragolumab
DrugBank: Tiragolumab (DB16409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiragolumab 600 mg plus atezolizumab 1,200 mg and carboplatin/etoposide (CE)
Trial: 37976444
Drug: Control (placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (placebo plus atezolizumab 1,200 mg and CE)
Trial: 37976633
Drug: pembrolizumab 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pembrolizumab 200 mg Q3W intravenously for up to 35 cycles
Trial: 37976633
Drug: chemotherapy (treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: chemotherapy (treatment of physician's choice per local/country guidelines)
Trial: 37977105
Drug: First-line treatment
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: First-line treatment for HR+/HER2- mBC in women aged <40
Trial: 37977105
Drug: First-line treatment
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: First-line treatment for HR+/HER2- mBC in women aged 40-69
Trial: 37977105
Drug: First-line treatment
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: First-line treatment for TN mBC in women aged <40
Trial: 37977105
Drug: First-line treatment
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: First-line treatment for TN mBC in women aged 40-69
Trial: 37977105
Drug: First-line treatment
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: First-line treatment for HER2+ mBC in women aged <40
Trial: 37977105
Drug: First-line treatment
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: First-line treatment for HER2+ mBC in women aged 40-69
Trial: 37977178
Drug: Self-reported adherence
RxNorm normalized name: black imported fire ant allergenic extract
DrugBank: Solenopsis richteri (DB11026)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-reported adherence to antiretroviral therapy (ARV)
Trial: 37977257
Drug: Choice architecture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Choice architecture intervention (banner of daily school meal menu, waterproof tablecloths, posters on healthy eating habits, playful names displays, new containers for fruits, colored footprints) for one month
Trial: 37977713
Drug: Lower dose
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower dose (1.3 × 10^14 vg/kg)
Trial: 37977713
Drug: Higher dose
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher dose (1.3 × 10^15 vg/kg)
Trial: 37977865
Drug: Tight blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tight blood pressure control with norepinephrine infusion targeting intraoperative MAP ≥85 mm Hg
Trial: 37977903
Drug: Serplulimab plus
RxNorm normalized name: Serplulimab
DrugBank: Serplulimab (DB17451)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serplulimab plus chemotherapy (etoposide and carboplatin) for four to six cycles, followed by maintenance therapy with serplulimab for up to 2 years.
Trial: 37977942
Drug: C difficile
RxNorm normalized name: Clostridioides difficile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C difficile vaccine (200 μg total toxoid)
Trial: 37977942
Drug: C difficile
RxNorm normalized name: Clostridioides difficile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C difficile vaccine
Trial: 37978159
Drug: Intravenous acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous acetaminophen (25 mg/kg loading dose then 10 mg/kg/6 h for 5 days)
Trial: 37978159
Drug: Intravenous acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous acetaminophen (dose level 1)
Trial: 37978159
Drug: Intravenous acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous acetaminophen (dose level 2)
Trial: 37978284
Drug: Tovorafenib (420
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tovorafenib (420 mg)
Trial: 37978309
Drug: Moderate-intensity statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate-intensity statin with ezetimibe combination therapy (rosuvastatin 10 mg plus ezetimibe)
Trial: 37978309
Drug: High-intensity statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-intensity statin (rosuvastatin 20 mg) monotherapy
Trial: 37978378
Drug: Cellular bone
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cellular bone allograft (CBA) used as primary graft material (≥ 50% by volume) with augmentation up to 50%
Trial: 37978474
Drug: Control side
RxNorm normalized name: cured fat, pork side bacon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control side (no i-PRF injection)
Trial: 37978528
Drug: Strategies to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strategies to develop stakeholder interrelationships (35% in Preparation phase, 31% in Implementation phase)
Trial: 37978528
Drug: Strategies in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strategies in the use iterative and evaluative approaches cluster (24% in Preparation phase, 18% in Implementation phase)
Trial: 37978951
Drug: Everolimus, 5
RxNorm normalized name: Everolimus, 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus, 5 mg/m² orally
Trial: 37979133
Drug: PVAB regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PVAB regimen (prednisone 40 mg/m2 days 1-5, vinblastine 6 mg/m2 day 1, doxorubicin 40 mg/m2 day 1, bendamustine 120 mg/m2 day 1) every 21 days for 6 cycles
Trial: 37979218
Drug: d-cycloserine augmentation
RxNorm normalized name: D-(+)-cycloserine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d-cycloserine augmentation with group exposure therapy
Trial: 37979594
Drug: High-dose short-course
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose short-course oral primaquine (7 mg/kg over 7 days)
Trial: 37979594
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care (single dose oral primaquine of 0.25 mg/kg)
Trial: 37979594
Drug: High-dose short-course
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose short-course oral primaquine
Trial: 37980367
Drug: Enzalutamide plus
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Enzalutamide plus CC-115 (5 mg twice a day)
Trial: 37980494
Drug: Enhanced usual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced usual care (EUC) (primary care treatment as usual, printed overdose prevention educational materials, educational video on cancer screening)
Trial: 37980511
Drug: Bladder-sparing therapies
RxNorm normalized name: Sus scrofa urinary bladder preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bladder-sparing therapies (BST)
Trial: 37980875
Drug: Group iterative
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group iterative multiple model estimation (GIMME) applied to examine the relationships between various emotions and suicidal ideation (SI) among individuals with borderline personality disorder who underwent Dialectical Behavior Therapy.
Trial: 37980921
Drug: Systemic and
RxNorm normalized name: Estradiol and Levonorgestrel Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic and local therapy group (n=53)
Trial: 37980921
Drug: Systemic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic therapy only group (n=51)
Trial: 37980924
Drug: Apixaban (weight-adjusted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apixaban (weight-adjusted twice-daily)
Trial: 37981049
Drug: SY-009 (1.0-4.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SY-009 (1.0-4.0 mg)
Trial: 37981596
Drug: Deucravacitinib (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deucravacitinib (both doses)
Trial: 37981665
Drug: Curcumin gel
DrugBank: Curcumin sulfate (DB14635)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin gel applied weekly for four weeks after SRP
Trial: 37981892
Drug: Cyclophosphamide plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) and 'on-demand' plerixafor
Trial: 37982276
Drug: High-sensitivity C-reactive
RxNorm normalized name: Fluorimax Sensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-sensitivity C-reactive protein quartile 4 (≥4.0 mg/L)
Trial: 37982381
Drug: Single LMWH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single LMWH injection
Trial: 37982575
Drug: Oral ERα
RxNorm normalized name: Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ERα degraders
Trial: 37982585
Drug: Atazanavir/ritonavir 300/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atazanavir/ritonavir 300/100 mg twice a day (BID) with rifampicin 600 mg OD (PK3)
Trial: 37982585
Drug: Atazanavir/ritonavir 300/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atazanavir/ritonavir 300/100 mg once daily (OD) with rifampicin 600 mg (PK2)
Trial: 37982585
Drug: Atazanavir/ritonavir 300/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atazanavir/ritonavir 300/100 mg BID with rifampicin 1200 mg OD (PK4)
Trial: 37982585
Drug: Atazanavir/ritonavir 300/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atazanavir/ritonavir 300/100 mg OD (baseline, PK1)
Trial: 37982827
Drug: Palbociclib (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palbociclib (125 mg/day for 21 days per cycle, administered for two cycles during IMRT) + Cetuximab + Intensity-modulated radiotherapy (IMRT)
Trial: 37982982
Drug: Educational brochure
RxNorm normalized name: DIABETES PATIENT EDUCATION PACK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Educational brochure on deprescribing mailed to patients, clinician notification about brochure mailings, and monthly educational tip sheets for primary care clinicians.
Trial: 37983228
Drug: Intravenous acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous acetaminophen and fentanyl
Trial: 37983375
Drug: GP-2250 (misetionamide)
RxNorm normalized name: GPS
DrugBank: Galinpepimut-S (DB17271)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GP-2250 (misetionamide) administered daily for 28 days at doses of 500 mg/kg, 1000 mg/kg, and 250 mg/kg
Trial: 37983375
Drug: Vehicle (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle (10 ml/kg) administered daily for 28 days
Trial: 37983769
Drug: 3-in-1 single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-in-1 single capsule with bismuth, metronidazole, and tetracycline
Trial: 37983769
Drug: Quadruple therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadruple therapy with bismuth
Trial: 37983769
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy with levofloxacin
Trial: 37983769
Drug: 3-in-1 single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-in-1 single capsule
Trial: 37983769
Drug: Triple schedules,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple schedules, sequential, or concomitant regimen with metronidazole
Trial: 37983823
Drug: Carotid FTc
RxNorm normalized name: (-)-FTC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carotid FTc combined with perioperative fluid therapy (8 ml/kg of balanced crystalloids)
Trial: 37983823
Drug: No perioperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No perioperative fluid therapy
Trial: 37984383
Drug: Vosoritide (30·0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vosoritide (30·0 μg/kg for infants aged 0-23 months; 15·0 μg/kg for children aged 24-59 months)
Trial: 37984453
Drug: RPT193 (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RPT193 (oral CCR4 antagonist), once-daily treatment
Trial: 37984741
Drug: 100 g
RxNorm normalized name: Berri-Freez 4.5 GM per 100 GM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 g prune/d
Trial: 37984741
Drug: 50 g
RxNorm normalized name: glucose 50 g/296 mL oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 g prune/d
Trial: 37984940
Drug: Angiotensin II
RxNorm normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Angiotensin II as a second-line vasopressor infusion during liver transplantation.
Trial: 37984940
Drug: Saline placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline placebo as the second-line vasopressor infusion during liver transplantation.
Trial: 37985359
Drug: Ibrutinib (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibrutinib (oral Bruton tyrosine kinase inhibitor), lenalidomide (15 mg days 1-21 cycle 1; 20 mg cycles 2-12), and rituximab (375 mg/m2) for 12 cycles of 28 days each.
Trial: 37985386
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy with immunotherapy (NACI)
Trial: 37985697
Drug: 2-mg CPC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-mg CPC buccal tablet
Trial: 37985968
Drug: eptinezumab 100
RxNorm normalized name: EPTINEZUMAB 100 mg in 1 mL INTRAVENOUS INJECTION [Vyepti]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eptinezumab 100 mg (continuation from placebo)
Trial: 37985968
Drug: eptinezumab 300
RxNorm normalized name: Eptinezumab
DrugBank: Eptinezumab (DB14040)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: eptinezumab 300 mg (continuation from placebo)
Trial: 37985994
Drug: Machine learning
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Machine learning (ML) models for assessing the risk of heart failure (HF) occurrence
Trial: 37985994
Drug: Machine learning
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Machine learning (ML) models for assessing the risk of heart failure (HF) occurrence in MASLD(+) patients
Trial: 37985994
Drug: Machine learning
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Machine learning (ML) models for assessing the risk of heart failure (HF) occurrence in MASLD(-) patients
Trial: 37986155
Drug: ECOHIS (Early
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ECOHIS (Early Childhood Oral Health Impact Scale)
Trial: 37986155
Drug: Child-OIDP (Child
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Child-OIDP (Child Oral Impact on Daily Performance)
Trial: 37986556
Drug: Nivolumab 240
RxNorm normalized name: nivolumab 240 MG in 24 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab 240 mg i.v. bi-weekly for up to 12 months (Part 1)